Skip to main content
. 2012 May 25;7(5):e37787. doi: 10.1371/journal.pone.0037787

Figure 5. Inhibition of the Slc10a2 protein improves plasma glucose and TGs in ob/ob mice.

Figure 5

Ob/ob mice were treated with a specific Slc10a2 protein inhibitor, (AZD7806), or control vehicle (vehicle) (see experimental procedures). (A) fasting levels of blood glucose and plasma insulin. (B) plasma total TGs and cholesterol. (C) Hepatic mRNA levels of fibroblast growth factor 21 (FGF21) and cholesterol 7α-hydroxylase (Cyp7a1). (D) Liver cholesterol and TGs. (E) Distal ileum mRNA levels of FGF15, small heterodimer partner (Shp), Ileal BA binding protein (Ibabp) and farnesoid X receptor (Fxr) from ob/ob animals treated with a Slc10a2 protein inhibitor. mRNA levels of the control vehicle treated animals are normalized to 1. Data are represented as mean ± standard error (SEM). Significances of differences between groups was tested by Student’s t test, a p-value <0.05 is denoted *. P<0.01 is denoted **.